Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
185 results
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. [Randomized Controlled Trial]
  • NEJMN Engl J Med 2019 04 18; 380(16):1509-1524
  • Lopes RD, Heizer G, … AUGUSTUS Investigators
  • CONCLUSIONS: In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS number, NCT02415400.).
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. [Randomized Controlled Trial]
  • NEJMN Engl J Med 2019 01 24; 380(4):347-357
  • Wiviott SD, Raz I, … DECLARE–TIMI 58 Investigators
  • CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 number, NCT01730534 .).
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. [Randomized Controlled Trial]
  • NEJMN Engl J Med 2018 11 29; 379(22):2097-2107
  • Schwartz GG, Steg PG, … ODYSSEY OUTCOMES Committees and Investigators
  • CONCLUSIONS: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES number, NCT01663402 .).
  • The First Brazilian Registry of Hypertension. [Letter]
  • AHAm Heart J 2018; 205:154-157
  • Lopes RD, Barroso WKS, … RBH Investigators
  • A systematic, nationwide assessment of care of patients with hypertension in Brazil is needed. The objective of the First National Registry of Patients with Hypertension in Brazil is to evaluate the …
  • Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. [Randomized Controlled Trial]
  • NEJMN Engl J Med 2018 10 04; 379(14):1332-1342
  • Zannad F, Anker SD, … COMMANDER HF Investigators
  • CONCLUSIONS: Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly lower rate of death, myocardial infarction, or stroke than placebo among patients with worsening chronic heart failure, reduced left ventricular ejection fraction, coronary artery disease, and no atrial fibrillation. (Funded by Janssen Research and Development; COMMANDER HF number, NCT01877915 .).
New Search Next